Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Janux Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell.
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS
PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers
JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities
PK exposure demonstrated TRACTr activation with lack of TCE accumulation
No treatment-emergent ADA titers observed
Janux to host virtual investor event today at 4:00 PM Eastern Time
Janux Therapeutics Inc (NASDAQ: JANX) announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration-